Dashboard
Poor Management Efficiency with a low ROCE of 6.67%
- The company has been able to generate a Return on Capital Employed (avg) of 6.67% signifying low profitability per unit of total capital (equity and debt)
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 5.77
Poor long term growth as Net Sales has grown by an annual rate of 2.21% over the last 5 years
Negative results in Jun 25
With ROCE of 4.03%, it has a risky valuation with a 1.04 Enterprise value to Capital Employed
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 3,515 Million (Small Cap)
73.00
NA
0.00%
0.12
2.07%
1.12
Total Returns (Price + Dividend) 
Envista Holdings Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Envista Holdings Corp. Experiences Evaluation Revision Amidst Mixed Financial Metrics
Envista Holdings Corp. has recently adjusted its valuation, with its stock price slightly increasing. Over the past year, the company has experienced a stock return of 7.05%, lagging behind the S&P 500. Key financial metrics reveal a mixed valuation landscape compared to industry peers, indicating diverse financial health within the sector.
Read MoreIs Envista Holdings Corp. technically bullish or bearish?
As of 12 September 2025, the technical trend for Envista Holdings Corp. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. The Bollinger Bands also reflect a bullish stance on the weekly and mildly bullish on the monthly. Daily moving averages are bullish, supporting the overall mildly bullish outlook. However, the OBV shows a mildly bearish trend on the monthly, which could signal some caution. In terms of performance, Envista has underperformed the S&P 500 over the past week and year, with returns of -2.68% and 9.65% respectively, compared to the S&P 500's returns of 1.05% and 17.14%. Overall, the current technical stance is mildly bullish, but the mixed signals suggest a need for careful monitoring....
Read MoreIs Envista Holdings Corp. overvalued or undervalued?
As of 7 August 2025, the valuation grade for Envista Holdings Corp. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company is currently considered undervalued, supported by a P/E ratio of 73, an EV to EBITDA of 13.83, and a Price to Book Value of 1.05. In comparison to peers, QIAGEN NV has a P/E of 24.20, while Masimo Corp. shows a significantly higher P/E of 179.74, reinforcing Envista's relative attractiveness. Despite the positive valuation outlook, Envista's recent stock performance has lagged behind the S&P 500, with a year-to-date return of 9.02% compared to the index's 12.22%. Over the past three years, the stock has declined by 38.69%, while the S&P 500 has gained 70.41%, highlighting the need for cautious optimism regarding its future performance....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 105 Schemes (75.46%)
Held by 177 Foreign Institutions (17.32%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 10.57% vs -5.51% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 46.67% vs 1,400.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -2.18% vs -0.10% in Dec 2023
YoY Growth in year ended Dec 2024 is -1,016.37% vs -142.10% in Dec 2023






